NCT07343635

The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea: A Prospective Parallel Controlled Single-blind Cohort Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 186 (estimated)
• Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The efficacy and safety of anti-inflammation treatment (Hirudoid introduction followed by yellow light therapy) combined with tofacitinib and doxycycline in Chinese adult patients with mild to moderate erythematous telangiectatic rosacea: A prospective parallel controlled single-blind cohort study

Conditions

• Erythematotelangiectatic Rosacea

Interventions

Type	Name	Description
DRUG	Doxycycline	Doxycycline 100 mg orally once daily
DRUG	Hydroxychloroquine	Hydroxychloroquine 200 mg orally twice daily.
DRUG	Tofacitinib	Tofacitinib 5mg orally twice daily.
DEVICE	Anti-inflammatory Treatment (Hirudoid Introduction Followed by Yellow Light Therapy)	Topical application of Hirudoid followed by yellow light therapy (wavelength 590 nm, duration 20 minutes per session, once weekly)

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-07-01
• Completion: 2027-07-01
• First posted: 2026-01-15
• Last updated: 2026-03-24

Locations

1 site across 1 country: China